Gilead Sciences has bolstered its position in the development of next-generation cancer cell therapies with a deal to absorb Tmunity Therapeutics into its Kite unit.

Gilead’s $11.9 billion purchase of Kite Pharma in 2017 didn’t follow the script, with two big write-downs in the value of the asset since then, but a fresh approval for a CAR-T therapy could ...

On August 24, kites of colour will fill the skies of Galle Face Green marking the 5th edition of the Derana Colombo International Kite Festival 2025. Fifty-five international kite fliers from 25 ...